Table 3

Baseline patient-reported outcome scores. Data represent mean (SD) unless otherwise stated.

MeasurePlacebo, n = 153Fostamatinib 150 mg qd, n = 152Fostamatinib 100 mg bid, n = 152
Pain, 0–100 mm visual analog scale56.3 (21.9)57.1 (22.1)58.3 (24.1)
Global assessment of disease activity, 0–100 mm visual analog scale55.3 (22.0)54.3 (23.8)56.1 (23.9)
HAQ-DI, 0–31.5 (0.7)1.5 (0.7)1.5 (0.7)
FACIT-fatigue, 0–5227.1 (11.2)28.6 (11.3)28.8 (11.5)
SF-36 physical component summary32.4 (8.0)32.6 (7.8)32.7 (8.0)
SF-36 mental component summary39.9 (11.1)41.7 (11.6)39.4 (12.2)
SF-36 domains
 Physical functioning30.5 (10.8)30.9 (9.7)30.3 (10.5)
 Role physical32.4 (9.2)33.2 (9.0)32.3 (9.4)
 Bodily pain33.9 (7.8)34.4 (8.3)34.0 (8.0)
 General health35.6 (8.5)36.6 (8.4)35.0 (8.6)
 Vitality41.6 (9.6)42.0 (9.7)42.0 (10.4)
 Social function35.8 (10.5)38.0 (11.1)36.3 (11.4)
 Role emotional32.8 (12.3)34.2 (12.7)31.6 (13.1)
 Mental health39.1 (11.2)40.7 (10.8)38.8 (12.4)
  • Norm-based scores based on 1998 US general population. bid: twice daily; qd: once daily; HAQ-DI: Health Assessment Questionnaire-Disability Index; FACIT: Functional Assessment of Chronic Illness Therapy; SF-36: Medical Outcomes Study Short Form-36.